ArticleGene therapy2005
Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice.
Article in Gene therapy, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 39 citations in OpenAlex.
- Genetically engineered mouse model of HPV16 E6-E7 with vaginal-cervical intraepithelial neoplasia and decreased immunity.Heliyon · 2024Article
- Cancer vaccine strategies using self-replicating RNA viral platforms.Cancer gene therapy · 2023Review
- Development and Applications of Viral Vectored Vaccines to Combat Zoonotic and Emerging Public Health Threats.Vaccines · 2020Review
- An alphavirus-based therapeutic cancer vaccine: from design to clinical trial.Cancer immunology, immunotherapy : CII · 2019Review
- Therapeutic vaccines for high-risk HPV-associated diseases.Papillomavirus research (Amsterdam, Netherlands) · 2018Review
- Targeted immunotherapy of high-grade cervical intra-epithelial neoplasia: Expectations from clinical trials.Molecular and clinical oncology · 2018Article
- Long-term toxicity, pharmacokinetics and immune effects of a recombinant adenovirus vaccine expressing human papillomavirus 16 E6 and E7 proteins (HPV16 E6E7-Ad5 Vac) in primates.American journal of translational research · 2018Article
- Targeting Head and Neck Cancer by Vaccination.Frontiers in immunology · 2018Review
- Correlation of Circulating CD64Cancer microenvironment : official journal of the International Cancer Microenvironment Society · 2017Article
- Perspectives for therapeutic HPV vaccine development.Journal of biomedical science · 2016Review
- Current state in the development of candidate therapeutic HPV vaccines.Expert review of vaccines · 2016Review
- Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases.Human vaccines & immunotherapeutics · 2016Review
- Antigen design enhances the immunogenicity of Semliki Forest virus-based therapeutic human papillomavirus vaccines.Gene therapy · 2015Article
- From tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumors.Clinical & developmental immunology · 2011Review
- Immunotherapy for cervical cancer: Research status and clinical potential.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2010Review
- Perspectives for preventive and therapeutic HPV vaccines.Journal of the Formosan Medical Association = Taiwan yi zhi · 2010Review
- Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen.Vaccine · 2009Article
- Therapeutic human papillomavirus vaccines: current clinical trials and future directions.Expert opinion on biological therapy · 2008Review
- Viral vector-based prime-boost immunization regimens: a possible involvement of T-cell competition.Gene therapy · 2008Article
- Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions.International journal of cancer · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite promising preclinical results of various therapeutic anticancer immunization strategies, these approaches may not be effective enough to eradicate tumors in cancer patients. While most animal models are based on fast-growing transplantable tumors, malignancies in, for example, cervical cancer patients in general develop much more slowly, which may lead to immune suppression and/or immune tolerance. As a consequence, the immunomodulating signal of any therapeutic immunization regimen should be sufficiently potent to overcome this immunocompromised condition. In previous studies, we demonstrated that an experimental vaccine against human papillomavirus (HPV)-induced cervical cancer, based on Semliki Forest virus (SFV), induces robust HPV-specific cellular immune responses in mice. Now we studied whether this strategy is potent enough to also prime a cellular immune response in immune-tolerant HPV transgenic mice, in which CTL activity cannot be induced using protein or DNA vaccines. We demonstrate that, depending on the route of immunization, SFV-expressing HPV16 E6 and E7 indeed has the capacity to induce HPV16 E7-specific cytotoxic T cells in HPV-transgenic mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.